Şizofreni Hastalarında Değişen Eritrosit Deformabilitesi ve Antioksidan Enzim Düzeyleri

Abstract

Amaç: Şizofreni, etiyolojisi tam olarak açıklanamamış önemli mental hastalıklardan biridir. Serbest radikallerin merkezi sinir sisteminde membranlara hasar verebileceği ve bunun da şizofreninin fizyopatolojisinde rol oynayabileceğine dair veriler mevcuttur. Eritrositlerin de psikiyatrik hastalıklarda periferik bir gösterge olarak kullanılabileceği öngörülmektedir. Bizler bu çalışmada şizofrenli hastaların antioksidan kapasite ve lipid peroksidasyon düzeylerini ölçerek bu parametrelerin eritrositlerin deformabilite özellikleri üzerindeki etkilerini araştırmayı amaçladık.

Hastalar ve Yöntem: Yirmi şizofreni hastası ve 20 sağlıklı kontrol çalışmaya dahil edildi. Antioksidan enzimler ve lipid peroksidasyon düzeyleri spektrofotometrik olarak, eritrosit deformabilite düzeyleri ise shear stres difraktometresi aracılığıyla ölçülmüştür.

Bulgular: Hasta grubunda kontrol grubuna göre eritrosit deformabilite özelliklerinin azaldığı, lipid peroksidasyonu düzeylerinin arttığı, antioksidan enzim düzeylerinde ise değişiklikler olduğu gözlenmiştir (P<0,05).

Sonuç: Serbest radikallerin şizofrenide eritrosit deformabilitesi üzerinde olumsuz rol oynadığı ve şizofreni hastalarında antioksidan düzeylerinin değiştiği anlaşılmıştır. (Marmara Üniversitesi Tıp Fakültesi Dergisi 2012;25:133-7)

Anahtar Kelimeler: Antioksidan enzimler, Eritrosit, Lipid peroksidasyonu, Eritrosit deformabilitesi, Şizofreni

Keywords

• Antioksidan enzimler, Eritrosit, Lipid peroksidasyonu,Eritrosit deformabilitesi, Şizofreni

References

1. 1. Altuntas İ, Aksoy H, Coskun İ, Çayköylü A, Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000;38:1277-81. doi:10.1515/CCLM.2000.201
2. 2. Mahadik SP, Mukherjee S, Horrobin DF, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res 1996;63:133-42. doi:10.1016/0165-1781(96)02899-5
3. 3. Yao JK, Van Kammen DP, Walker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 2000;42:7-17. doi:10.1016/0920-9964(94)90045-0
4. 4. Reddy RD, Keshavan MS, Yao JK. Reduced red blood cell membrane essential polyunsaturated fatty acids in first-episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 2004;30:901-11.
5. 5. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005;16:386-91. doi:10.1080/09537100500128872
6. 6. Hamazaki K, Choi KH, Kim HY. Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. J Psychiatr Res 2010;44:688- 93. doi:10.1016/j.jpsychires.2009.11.017
7. 7. Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G. Oxidative stress and aging. J Nephrol 2010;23 Suppl 15:S29-36. doi:10.1142/9789812775733_0059
8. 8. Pazvantoglu O, Selek S, Okay IT, et al. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009;63:693-700. doi:10.1111/j.1440-1819.2009.02015.x

9. 9. Simsek F. Serbest oksijen radikalleri, antioksidanlar ve lipid peroksidasyonu. Turkiye Klinikleri J Pediatr 1999;8:42-7.
10. 10. Fendri C,Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 2006;32(2 Pt 1):244-52.
11. 11. Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr Neurosci 2002;5:291-309. doi:10.1080/1028415021000033767
12. 12. Van Rensburg SJ, Smuts CM, Hon D, et al. Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metab Brain Dis 2009 Dec;24:659- 72. doi:10.1080/1028415021000033767
13. 13. Sethom MM, Fares S, Bouaziz N, et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2010;83:131-6. doi:10.1016/j.plefa.2010.07.001
14. 14. Ruef P, Pöschl JMB, Linderkamp O, The Rheodyn SSD for measuring erythrocyte deformability. Biorheology 1995;32:357-8. doi:10.1016/0006-355X(95)92349-F
15. 15. Draper H, Hadley M. Malondialdehyde determination as an index of lipid peroxidation. Methods Enzymol 1990;186:421-31. doi:10.1016/0076-6879(90)86135-I
16. 16. Paglia DE, Valentine WN. Studies on the quantative and qualitative characterization of erythrocye glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
17. 17. Beers RF, Sizer IW. A spectrophotemetric method for measuring the breakdown of hydrogen peroxide by catalase.J Biol Chem 1952;95:133-40.
18. 18. Lück H. Catalase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. Weinheim: Verlag Chemie-GMBH, 1965:885-94.
19. 19. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
20. 20. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizopr Res 1996;19:1-7. doi:10.1016/0920-9964(95)00049-6
21. 21. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002;20:171-5. doi:10.1002/cbf.940
22. 22. Srivastava N, Barthwal MK, Dalal PK, et al. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 2001;158:140-5. doi:10.1007/s002130100860
23. 23. Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B 2006;7:981-6. doi:10.1631/jzus.2006.B0981
24. 24. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006;81:291-300. doi:10.1016/j.schres.2005.10.011
25. 25. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E. Oxidativeantioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1164-9. doi:10.1016/j.pnpbp.2007.03.008
26. 26. Morera AL, Intxausti A, Abreu-Gonzalez P. Winter/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research. World J Biol Psychiatry 2009;10(4 Pt 2):576-80. doi:10.1080/15622970801901802
27. 27. Othmen LB, Mechri A, Fendri C, Bost GC, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:155-9. doi:10.1016/j.pnpbp.2007.08.003
28. 28. Akyol O, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005. doi:10.1016/S0278-5846(02)00220-8
29. 29. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1677-81. doi:10.1016/j.pnpbp.2008.07.001
30. 30. Herken H, Uz E, Ozyurt H, Sögüt S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001;6:66-73. doi:10.1038/sj.mp.4000789
31. 31. Mohandas N, Chasis JA, Shohet SB. The influence of membrane skeleton on red cell deformability, membrane material properties, and shape. Semin Hematol 1983;20:225-42.
32. 32. Stuart J, Nash GB. Red cell deformability and haematological disorders. Blood Rev 1990;4:141-7. doi:10.1016/0268-960X(90)90041-P
33. 33. Mohandas N, Phillips WM, Bessis M. Red blood cell deformability and hemolytic anemias. Semin Hematol 1979;16:95-114.
34. 34. Baskurt OK. The role of spleen in suppressing the rheological alterations in circulating blood. Clin Hemorheol Microcirc 1999;20:181-8.
35. 35. Fung YC. Theoretical considerations of the elasticity of red cells and small blood vessels. Fed Proc 1966;25:1761-72.
36. 36. Cicco G, Pirrelli A. Red blood cell (RBC) deformability, RBC aggregability and tissue oxygenation in hypertension. Clin Hemorheol Microcirc 1999;21:169-77.
37. 37. Cicco G, Cicco S. Hemorheology and microcirculation in some pathologies of internal medicine Minerva Med 2007;98:625-31.
38. 38. Lenz C, Rebel A, Waschke KF, Koehler RC, Frietsch T. Blood viscosity modulates tissue perfusion: sometimes and somewhere. Transfus Altern Transfus Med 2008;9:265-72.
39. 39. Nakashima H, Ueda K, Yasugawa S, Katsuragi S, Kimura T, Miyakawa T. Erythrocyte deformability in schizophrenic patients. Psychiatry Clin Neurosci 1996;50:191-4. doi:10.1111/j.1440-1819.1996.tb02741.x
40. 40. Esrefoglu M. Hücre hasarı ve ölümü: Oksidatif stres ve antiksidan savunma sistemi. Turkiye Klinikleri J Med Sci 2009;29:1660-76.
41. 41. Tylec A, Jarzab A, Stryjecka-Zimmer M, Wójcicka A. Stress oxidative in schizophrenia. Pol Merkur Lekarski 2007;23:74-7.